107 related articles for article (PubMed ID: 8759769)
1. Susceptibility of HIV-1 plasma virus to complement-mediated lysis. Evidence for a role in clearance of virus in vivo.
Sullivan BL; Knopoff EJ; Saifuddin M; Takefman DM; Saarloos MN; Sha BE; Spear GT
J Immunol; 1996 Aug; 157(4):1791-8. PubMed ID: 8759769
[TBL] [Abstract][Full Text] [Related]
2. Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection.
Montefiori DC; Cornell RJ; Zhou JY; Zhou JT; Hirsch VM; Johnson PR
Virology; 1994 Nov; 205(1):82-92. PubMed ID: 7526538
[TBL] [Abstract][Full Text] [Related]
3. Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells.
Brasoveanu LI; Altomonte M; Fonsatti E; Colizzi F; Coral S; Nicotra MR; Cattarossi I; Cattelan A; Natali PG; Maio M
Lab Invest; 1996 Jan; 74(1):33-42. PubMed ID: 8569195
[TBL] [Abstract][Full Text] [Related]
4. Host cell-derived complement control proteins CD55 and CD59 are incorporated into the virions of two unrelated enveloped viruses. Human T cell leukemia/lymphoma virus type I (HTLV-I) and human cytomegalovirus (HCMV).
Spear GT; Lurain NS; Parker CJ; Ghassemi M; Payne GH; Saifuddin M
J Immunol; 1995 Nov; 155(9):4376-81. PubMed ID: 7594597
[TBL] [Abstract][Full Text] [Related]
5. Membrane-bound regulators of complement activation in uveal melanomas. CD46, CD55, and CD59 in uveal melanomas.
Goslings WR; Blom DJ; de Waard-Siebinga I; van Beelen E; Claas FH; Jager MJ; Gorter A
Invest Ophthalmol Vis Sci; 1996 Aug; 37(9):1884-91. PubMed ID: 8759358
[TBL] [Abstract][Full Text] [Related]
6. Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction.
Saifuddin M; Hedayati T; Atkinson JP; Holguin MH; Parker CJ; Spear GT
J Gen Virol; 1997 Aug; 78 ( Pt 8)():1907-11. PubMed ID: 9266986
[TBL] [Abstract][Full Text] [Related]
7. Complement can neutralize HIV-1 plasma virus by a C5-independent mechanism.
Sullivan BL; Takefman DM; Spear GT
Virology; 1998 Sep; 248(2):173-81. PubMed ID: 9721226
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility of human trophoblast to killing by human complement and the role of the complement regulatory proteins.
Tedesco F; Narchi G; Radillo O; Meri S; Ferrone S; Betterle C
J Immunol; 1993 Aug; 151(3):1562-70. PubMed ID: 7687635
[TBL] [Abstract][Full Text] [Related]
9. Blockage of CD59 Function Restores Activities of Neutralizing and Nonneutralizing Antibodies in Triggering Antibody-Dependent Complement-Mediated Lysis of HIV-1 Virions and Provirus-Activated Latently Infected Cells.
Yang K; Lan J; Shepherd N; Hu N; Xing Y; Byrd D; Amet T; Jewell C; Gupta S; Kounga C; Gao J; Yu Q
J Virol; 2015 Sep; 89(18):9393-406. PubMed ID: 26136568
[TBL] [Abstract][Full Text] [Related]
10. Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59.
Clayton A; Harris CL; Court J; Mason MD; Morgan BP
Eur J Immunol; 2003 Feb; 33(2):522-31. PubMed ID: 12645951
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of resistance of HIV-1 primary isolates to complement-mediated lysis.
Takefman DM; Sullivan BL; Sha BE; Spear GT
Virology; 1998 Jul; 246(2):370-8. PubMed ID: 9657955
[TBL] [Abstract][Full Text] [Related]
12. Mechanism(s) promoting HIV-1 infection of primary unstimulated T lymphocytes in autologous B cell/T cell co-cultures.
Döpper S; Wilflingseder D; Prodinger WM; Stiegler G; Speth C; Dierich MP; Stoiber H
Eur J Immunol; 2003 Aug; 33(8):2098-107. PubMed ID: 12884283
[TBL] [Abstract][Full Text] [Related]
13. Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59.
Schmitz J; Zimmer JP; Kluxen B; Aries S; Bögel M; Gigli I; Schmitz H
J Clin Invest; 1995 Sep; 96(3):1520-6. PubMed ID: 7544808
[TBL] [Abstract][Full Text] [Related]
14. Cell-surface expression of complement restriction factors and sialyl Lewis antigens in oral carcinoma: relevance to chemo-immunotherapy.
Ravindranath NM; Nishimoto K; Chu K; Shuler C
Anticancer Res; 2000; 20(1A):21-6. PubMed ID: 10769630
[TBL] [Abstract][Full Text] [Related]
15. Activation of complement on the surface of cells infected by human immunodeficiency virus.
Spear GT; Landay AL; Sullivan BL; Dittel B; Lint TF
J Immunol; 1990 Feb; 144(4):1490-6. PubMed ID: 1968081
[TBL] [Abstract][Full Text] [Related]
16. Porcine complement regulators protect aortic smooth muscle cells poorly against human complement-induced lysis and proliferation: consequences for xenotransplantation.
Capey S; van den Berg CW
Xenotransplantation; 2005 May; 12(3):217-26. PubMed ID: 15807772
[TBL] [Abstract][Full Text] [Related]
17. Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1.
Saifuddin M; Parker CJ; Peeples ME; Gorny MK; Zolla-Pazner S; Ghassemi M; Rooney IA; Atkinson JP; Spear GT
J Exp Med; 1995 Aug; 182(2):501-9. PubMed ID: 7543140
[TBL] [Abstract][Full Text] [Related]
18. Diminished expression of cell-surface complement regulatory proteins in HIV-infected children and with HIV infection of peripheral blood mononuclear cells in vitro.
Jarvis JN; Taylor H; Long PM; Gutta PV; Pousak T; Fine N
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jul; 9(3):249-56. PubMed ID: 7540489
[TBL] [Abstract][Full Text] [Related]
19. Reduction of CD55 and/or CD59 in red blood cells of patients with HIV infection.
Terpos E; Sarantopoulos A; Kouramba A; Katsarou O; Stavropoulos J; Masouridi S; Karafoulidou A; Meletis J
Med Sci Monit; 2008 May; 14(5):CR276-280. PubMed ID: 18443552
[TBL] [Abstract][Full Text] [Related]
20. Complement-opsonized HIV: the free rider on its way to infection.
Stoiber H; Pruenster M; Ammann CG; Dierich MP
Mol Immunol; 2005 Feb; 42(2):153-60. PubMed ID: 15488605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
